Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(02): 159-161
DOI: 10.4103/wjnm.WJNM_22_19
Case Report

Neurolymphomatosis – Rare presentation in non-Hodgkin's lymphoma: The role of 18F-fluorodeoxyglucose positron-emission tomography and computerized tomography imaging

Nosheen Fatima
Department of Radiology, The Aga Khan University Hospital, Karachi, Pakistan
,
Maseeh Uz Zaman
Department of Radiology, The Aga Khan University Hospital, Karachi, Pakistan
,
Areeba Zaman
1   Department of Medicine, Civil Hospital Karachi, Karachi, Pakistan
,
Sidra Uz Zaman
2   Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Neurolymphomatosis (NLS) is infiltration of lymphoma cells into the peripheral or cranial nervous system and is a rare manifestation of non-Hodgkin lymphoma (NHL). Nerve biopsy is considered as the gold standard for diagnosis but not a preferred choice, and magnetic resonance imaging has lower reported sensitivity. 18F-Fluorodeoxyglucose (18FDG) positron-emission tomography and computerized tomography (PET/CT) has a higher sensitivity for diagnosing and assessing the neurological and nonneurological metabolic tumor volume and response evaluation to therapy. We present the case of a lady, known to have NHL in remission. She presented with a short history of severe pain and weakness of the right lower limb. Baseline and interim 18FDG PET/CT played a crucial role in diagnosing and assessing the extent of NLS and nonneurological disease burden and also in evaluation of response to treatment.

Keywords

18F-fluorodeoxyglucose positron-emission tomography and computerized tomography - magnetic resonance imaging - neurolymphomatosis - non-Hodgkin's lymphoma

Financial support and sponsorship

Nil.




Publication History

Received: 16 March 2019

Accepted: 01 July 2019

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Yoshiaki A, Yoshiaki U, Kentaro N, Masami T, Kosei M. Clinical features, diagnosis, and prognosis of 14 cases of neurolymphomatosis: Single institutional experience over 10 years. Blood 2016;128:3042.
  • 2 Shree R, Goyal MK, Modi M, Gaspar BL, Radotra BD, Ahuja CK, et al. The diagnostic dilemma of neurolymphomatosis. J Clin Neurol 2016;12:274-81.
  • 3 Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J 2012;18:463-8.
  • 4 Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, et al. Neurolymphomatosis: An international primary CNS lymphoma collaborative group report. Blood 2010;115:5005-11.
  • 5 Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol 2003;5:104-15.
  • 6 Currie S, Henson RA. Neurological syndromes in the reticuloses. Brain 1971;94:307-20.
  • 7 Chamberlain MC, Fink J. Neurolymphomatosis: A rare metastatic complication of diffuse large B-cell lymphoma. J Neurooncol 2009;95:285-8.
  • 8 Duchesne M, Mathis S, Corcia P, Richard L, Ghorab K, Jaccard A, et al. Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: A case series. Medicine (Baltimore) 2015;94:e394.
  • 9 Hong CM, Lee SW, Lee HJ, Song BI, Kim HW, Kang S, et al. Neurolymphomatosis on F-18 FDG PET/CT and MRI findings: A case report. Nucl Med Mol Imaging 2011;45:76-8.
  • 10 Salm LP, Van der Hiel B, Stokkel MP. Neurolymphomatosis diagnosed by (18) F-FDG PET-CT. Clin Nucl Med 2013;38:e261-2.
  • 11 Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: Diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol 2010;12:212-5.